Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

A model of hepatic steatosis with declined viability and function in a liver-organ-on-a-chip

Open access

Abstract

Nonalcoholic fatty liver disease (NAFLD) begins with benign steatosis caused by ectopic storage of triacylglycerols in the liver. Persistent steatosis, in combination with other genetic and environmental factors, leads to nonalcoholic steatohepatitis (NASH) characterized by functional impairment, inflammation, and fibrosis. However, it remains unclear how persistent steatosis directly contributes to the progression of NAFLD, which may represent a therapeutic target. The organ-on-a-chip (OOC) has emerged as a new culture platform to recapitulate human pathological conditions under which drug candidates can be screened. Here, we developed a simple OOC steatosis model using the Mimetas OrganoPlate with a human liver cell line, HepG2. Treating the HepG2 OOCs with fatty acid overload induced steatosis within 24 h. Moreover, persistent steatosis for 6 days impaired OOC viability and hepatic function, as measured by a WST-8 assay and albumin production, respectively. Lastly, the HepG2 OOCs were exposed to drugs being tested in clinical trials for NAFLD/NASH during the 6-day period. Pioglitazone improved the OOC viability while elafibranor reduced the steatosis in association with reduced viability and albumin production. In conclusion, we show that the HepG2 steatosis OOC model is a useful tool on which the efficacy and toxicity of various therapeutic candidates can be tested.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-023-44198-0

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Characterization of a liver OOC model with collagen ECM. HepG2 OOC cultures were maintained under two different conditions (A and B). HepG2 cells were embedded in collagen ECM containing no FBS (A) or 15% FBS (B) with William’s E medium including 10% FBS (A) or 0.5% FBS (B), respectively. Images of HepG2 OOCs were taken on Days 1, 3, 7, 10, and 14 at 5X, 10X, and 20X magnifications. Scale bar = 500 μm. Conditioned media were collected on Days 1, 3, 7, 10, and 14 to quantify LDH activity (C) and albumin concentrations (D) in HepG2 OOCs under Conditions A or B. Data are presented as mean ± SEM and analyzed by a two-way repeated measures ANOVA (n = 4–6). *p < 0.05 versus Day 1 of each condition. #p < 0.05 versus Condition A.
Figure 1 Characterization of a liver OOC model with collagen ECM. HepG2 OOC cultures were maintained under two different conditions (A and B). HepG2 cells were embedded in collagen ECM containing no FBS (A) or 15% FBS (B) with William’s E medium including 10% FBS (A) or 0.5% FBS (B), respectively. Images of HepG2 OOCs were taken on Days 1, 3, 7, 10, and 14 at 5X, 10X, and 20X magnifications. Scale bar = 500 μm. Conditioned media were collected on Days 1, 3, 7, 10, and 14 to quantify LDH activity (C) and albumin concentrations (D) in HepG2 OOCs under Conditions A or B. Data are presented as mean ± SEM and analyzed by a two-way repeated measures ANOVA (n = 4–6). *p < 0.05 versus Day 1 of each condition. #p < 0.05 versus Condition A.CC BY · PubMed Central
Figure 2 Induction of hepatic steatosis by exposure to fatty acids. HepG2 OOC cells were treated with vehicle (Veh, 1 mM NaOH), oleic acid (OA, 0.5 mM), palmitic acid (PA, 0.5 mM), or a mixture of OA and PA (OA + PA, 0.5 mM in total) for 24 h under Conditions A or B. (A–D) Representative fluorescence (A and C) or confocal (B and D) images of HepG2 OOC cells stained with Bodipy (green) or DAPI (blue). The confocal images were captured and processed using Zeiss ZEN 3.4 (blue edition) software. Bright-field (BF) images are shown in gray scale. (E and H) Quantitative analysis of Bodipy fluorescence in HepG2 OOCs. (F and I) LDH activity in conditioned medium of HepG2 OOC cultures. (G and J) Albumin concentration in conditioned medium of HepG2 OOC cultures. Data are presented as mean ± SEM and analyzed by one-way ANOVA (n = 3–6). *p < 0.05 versus Veh.
Figure 2 Induction of hepatic steatosis by exposure to fatty acids. HepG2 OOC cells were treated with vehicle (Veh, 1 mM NaOH), oleic acid (OA, 0.5 mM), palmitic acid (PA, 0.5 mM), or a mixture of OA and PA (OA + PA, 0.5 mM in total) for 24 h under Conditions A or B. (A–D) Representative fluorescence (A and C) or confocal (B and D) images of HepG2 OOC cells stained with Bodipy (green) or DAPI (blue). The confocal images were captured and processed using Zeiss ZEN 3.4 (blue edition) software. Bright-field (BF) images are shown in gray scale. (E and H) Quantitative analysis of Bodipy fluorescence in HepG2 OOCs. (F and I) LDH activity in conditioned medium of HepG2 OOC cultures. (G and J) Albumin concentration in conditioned medium of HepG2 OOC cultures. Data are presented as mean ± SEM and analyzed by one-way ANOVA (n = 3–6). *p < 0.05 versus Veh.CC BY · PubMed Central
Figure 3 Effects of 6-day persistent steatosis on cell viability and albumin production in HepG2 OOCs exposed to OA for 24 h. HepG2 OOC cells were treated with vehicle (Veh, 1 mM NaOH) or oleic acid (OA, 0.5 mM) for 24 h to induce steatosis and then maintained in complete media for Conditions A or B for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin concentration in conditioned medium. Data are presented as mean ± SEM and analyzed by Student’s t-test (n = 3–6). *p < 0.05 versus Veh.
Figure 3 Effects of 6-day persistent steatosis on cell viability and albumin production in HepG2 OOCs exposed to OA for 24 h. HepG2 OOC cells were treated with vehicle (Veh, 1 mM NaOH) or oleic acid (OA, 0.5 mM) for 24 h to induce steatosis and then maintained in complete media for Conditions A or B for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin concentration in conditioned medium. Data are presented as mean ± SEM and analyzed by Student’s t-test (n = 3–6). *p < 0.05 versus Veh.CC BY · PubMed Central
Figure 4 Effects of 6-day persistent steatosis on cell viability and albumin production in HepG2 OOCs exposed to OA + PA for 24 h. HepG2 OOC cells were treated with vehicle (Veh, 1 mM NaOH) or a mixture of oleic acid and palmitic acid (OA + PA, 0.5 mM in total) for 24 h to induce steatosis and then maintained in complete media for Conditions A or B for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin concentration in conditioned medium. Data are presented as mean ± SEM and analyzed by Student’s t-test (n = 4–6). *p < 0.05 versus Veh.
Figure 4 Effects of 6-day persistent steatosis on cell viability and albumin production in HepG2 OOCs exposed to OA + PA for 24 h. HepG2 OOC cells were treated with vehicle (Veh, 1 mM NaOH) or a mixture of oleic acid and palmitic acid (OA + PA, 0.5 mM in total) for 24 h to induce steatosis and then maintained in complete media for Conditions A or B for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin concentration in conditioned medium. Data are presented as mean ± SEM and analyzed by Student’s t-test (n = 4–6). *p < 0.05 versus Veh.CC BY · PubMed Central
Figure 5 Effects of metformin on fat accumulation, cell viability, and albumin production in HepG2 steatosis OOCs. HepG2 OOC cells were treated with vehicle (Veh, 1 mM NaOH), a mixture of oleic acid and palmitic acid (OA + PA, 0.5 mM in total) for 24 h to induce steatosis and then cultured in 10% or 0.5% FBS-containing media (Conditions A or B, respectively) with vehicle (serum-free medium) or metformin (0.01, 0.1, or 1 mM) for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin amount (ratio) in conditioned medium. Data are presented as mean ± SEM and analyzed by one-way ANOVA (n = 3–5).
Figure 5 Effects of metformin on fat accumulation, cell viability, and albumin production in HepG2 steatosis OOCs. HepG2 OOC cells were treated with vehicle (Veh, 1 mM NaOH), a mixture of oleic acid and palmitic acid (OA + PA, 0.5 mM in total) for 24 h to induce steatosis and then cultured in 10% or 0.5% FBS-containing media (Conditions A or B, respectively) with vehicle (serum-free medium) or metformin (0.01, 0.1, or 1 mM) for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin amount (ratio) in conditioned medium. Data are presented as mean ± SEM and analyzed by one-way ANOVA (n = 3–5).CC BY · PubMed Central
Figure 6 Effects of pioglitazone on fat accumulation, cell viability, and albumin production in HepG2 steatosis OOCs. HepG2 OOC cells were treated with a mixture of oleic acid and palmitic acid (OA + PA, 0.5 mM in total) for 24 h to induce steatosis and then cultured in 10% or 0.5% FBS-containing media (Conditions A or B, respectively) with vehicle (0.1% DMSO) or pioglitazone (Pio, 1 or 10 μM) for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin amount (ratio) in conditioned medium. Data are presented as mean ± SEM and analyzed by one-way ANOVA (n = 6–8). *p < 0.05 versus OA + PA in the absence of pioglitazone.
Figure 6 Effects of pioglitazone on fat accumulation, cell viability, and albumin production in HepG2 steatosis OOCs. HepG2 OOC cells were treated with a mixture of oleic acid and palmitic acid (OA + PA, 0.5 mM in total) for 24 h to induce steatosis and then cultured in 10% or 0.5% FBS-containing media (Conditions A or B, respectively) with vehicle (0.1% DMSO) or pioglitazone (Pio, 1 or 10 μM) for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin amount (ratio) in conditioned medium. Data are presented as mean ± SEM and analyzed by one-way ANOVA (n = 6–8). *p < 0.05 versus OA + PA in the absence of pioglitazone.CC BY · PubMed Central
Figure 7 Effects of elafibranor on fat accumulation, cell viability, and albumin production in HepG2 steatosis OOCs. HepG2 OOC cells were treated with a mixture of oleic acid and palmitic acid (OA + PA, 0.5 mM in total) for 24 h to induce steatosis and then cultured in 10% or 0.5% FBS-containing media (Conditions A or B, respectively) with vehicle (0.1% DMSO) or elafibranor (1, 10 or 50 μM) for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin amount (ratio) in conditioned medium. Data are presented as mean ± SEM and analyzed by one-way ANOVA (n = 4–6). *p < 0.05 versus OA + PA in the absence of elafibranor.
Figure 7 Effects of elafibranor on fat accumulation, cell viability, and albumin production in HepG2 steatosis OOCs. HepG2 OOC cells were treated with a mixture of oleic acid and palmitic acid (OA + PA, 0.5 mM in total) for 24 h to induce steatosis and then cultured in 10% or 0.5% FBS-containing media (Conditions A or B, respectively) with vehicle (0.1% DMSO) or elafibranor (1, 10 or 50 μM) for 6 days. (A and D) Quantitative analysis of Bodipy fluorescence. (B and E) WST-8-based viability assay. (C and F) Albumin amount (ratio) in conditioned medium. Data are presented as mean ± SEM and analyzed by one-way ANOVA (n = 4–6). *p < 0.05 versus OA + PA in the absence of elafibranor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 29

Metadata

Authors
Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K.
Affiliations
Mahidol University (TH)
Corresponding author
Muta, Kenjiro
Venue
Scientific Reports
Published
2023-10-09
Volume
13
Issue
1
Pages
17019-17019
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4387451531
Cited by
29
References
56
Citations by year
2026: 15 · 2025: 6 · 2024: 7 · 2023: 1
FWCI
5.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
  • The Program Management Unit for Competitiveness (C10F640323)
  • The National Research Council of Thailand (NRCT383/2563)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
hepatic steatosis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, HepG2 cells, fatty acid overload, cell viability, albumin synthesis, pioglitazone, elafibranor, drug screening
MeSH terms
Microphysiological Systems, Albumins, Humans, Inflammation, Liver, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A model of hepatic steatosis with declined viability and function in a liver-organ-on-a-chip. https://app.cochat.ai/papers/10.1038/s41598-023-44198-0
The paper
Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K. (2023). A model of hepatic steatosis with declined viability and function in a liver-organ-on-a-chip. Scientific Reports. https://doi.org/10.1038/s41598-023-44198-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.